Mode
Text Size
Log in / Sign up
N/A Completed N=36 Randomized Treatment

Pilot Dispensing Evaluation of a Plus Power Lens

Source: ClinicalTrials.gov NCT01228591 ↗
Enrolled (actual)
36
Serious AEs
0.0%
Results posted
Feb 2014
Primary outcomePrimary: Visual Acuity One Week After Lens Wear — 0.11; 0.10; 0.14; 0.14 LogMAR

Summary

The purpose of this study is to compare the performance of the ACUVUE® ADVANCE® Plus lenses against ACUVUE® ADVANCE® lenses in the plus power parameters.

Outcome Measures

OutcomeResultp-value
PRIMARY
Visual Acuity One Week After Lens Wear
0.11; 0.10; 0.14; 0.14; 0.12; 0.13
PRIMARY
Visual Acuity at Time of Initial Fit
0.13; 0.11; 0.16; 0.15; 0.14; 0.13
SECONDARY
Contact Lens Comfort Using Contact Lens User Experience (CLUE)
49.2; 50.7
SECONDARY
Subject Reported Vision Using Contact Lens User Experience (CLUE).
42.5; 39.9
SECONDARY
Contact Lens Comfort at Initial Fit Using Contact Lens User Experience (CLUE)
65.3; 59.0
SECONDARY
Subject Reported Vision at Initial Fit Using Contact Lens User Experience (CLUE)
46.7; 49.6

Eligibility Criteria

Inclusion Criteria

  • The subject must be at least 18 years of age and no more than 45 years of age.
  • The subject is a current spherical soft contact lens wearer and willing to wear the study lenses on a daily wear basis for the duration of the study (defined as a minimum of 6 hours with a minimum of at least 1 month's wear prior to the study).
  • The subject's optimal verified spherical equivalent distance correction must be between +1.00 and + 6.00D.
  • Any cylinder power must be ≤ 0.75D.
  • The subject must have visual acuity best correctable to 20/25+3 or better for each eye.
  • The subject must read and sign the Statement of Informed Consent.
  • The subject must appear able and willing to adhere to the instructions set forth in the clinical protocol.

Exclusion Criteria

  • Ocular or systemic allergies or disease which might interfere with contact lens wear.
  • Systemic disease or use of medication which might interfere with contact lens wear.
  • Clinically significant (grade 3 or 4) corneal edema, corneal vascularization, corneal staining, or any other abnormalities of the cornea which would contraindicate contact lens wear.
  • Clinically significant (grade 3 or 4) tarsal abnormalities or bulbar injection which might interfere with contact lens wear.
  • Any ocular infection.
  • Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
  • Pregnancy or lactation.
  • Diabetes.
  • Infectious diseases (e.g. hepatitis, tuberculosis) or an immuno-suppressive disease (e.g. HIV).
  • Habitual contact lens type is toric, bifocal, in monovision contact lens wear, or is worn as extended wear.
  • Need any near correction.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01228591). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search